EyePoint Pharmaceutics Inc. stock EYPT + 217.33% soared 362% on Monday morning after the company reported positive results from its Phase 2 trial for wet age related macular degeneration. The company stated that the study using vorolanib – a selective Tyrosine Kinase Inhibitor – and bioerodible Durasert E met the primary endpoint, as well as the key secondary endpoints, with both doses. This included a reduction of more than 80% in treatment burden. Nearly two-thirds were supplement-free for up to six months, while over 80% received only one or zero supplements up to six month. “Wet AMD” is a common and progressive disease that can last a lifetime. Patients can maintain their vision with frequent treatment. However, many end up being undertreated because of the high doses of short-acting anti VEGF treatments currently available. The company will release the complete dataset at Angiogenesis, Exudation, and Degeneration in February. The stock is up 89% year-to-date, while S&P500 SPX -0.53% is up 19.7%.